Your shopping cart is currently empty

Netivudine is a potent nucleoside reverse transcriptase inhibitor (NRTIs), a nucleoside analogue with anti-varicella zoster virus activity that can be used to treat human immunodeficiency virus (HIV) infection. Netivudine works by inhibiting reverse transcriptase, which reduces viral load in the body and slows the progression of the disease through its inhibitory effect.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $109 | In Stock | In Stock | |
| 5 mg | $270 | In Stock | In Stock | |
| 10 mg | $383 | In Stock | In Stock | |
| 25 mg | $575 | In Stock | In Stock | |
| 50 mg | $777 | In Stock | In Stock | |
| 100 mg | $1,050 | - | In Stock | |
| 200 mg | $1,370 | - | In Stock |
| Description | Netivudine is a potent nucleoside reverse transcriptase inhibitor (NRTIs), a nucleoside analogue with anti-varicella zoster virus activity that can be used to treat human immunodeficiency virus (HIV) infection. Netivudine works by inhibiting reverse transcriptase, which reduces viral load in the body and slows the progression of the disease through its inhibitory effect. |
| Targets&IC50 | VZV:0.6-3.8μM |
| In vitro | The phosphorylation of netivudine in VZV infected human cells is similar to that of sorivudine and the IC50 of netivudine for VZV ranges from 06-3.8 uM. Since, in HSV-infected cells, only the monophosphate is formed, netivudine shows no appreciable in vitro activity against HSV or other human herpesviruses.[1] |
| In vivo | The half-life of netivudine in humans is about 12-15 hand preliminary pharmacokinetic studies, employing oral doses of netivudine at 100 mg, 200 mg and 400 mg in young adults and healthy elderly volunteers, confirmed that concentrations of the drug substantially above the IC50 for VZV could be achieved and sustained with twice daily dosing.[2] The drug bioavailability was 21.1% and 24.6% in the young and elderly, respectively. An initial, open, dose-ranging study of netivudine in 31 elderly immunocompetent patients with localised herpes zoster with oral doses up to 200mg twice daily showed therapeutic benefits upon rash healing and pain and no significant adverse effects.[3] |
| Molecular Weight | 282.25 |
| Formula | C12H14N2O6 |
| Cas No. | 84558-93-0 |
| Smiles | O=C1N(C=C(C#CC)C(=O)N1)[C@@H]2O[C@H](CO)[C@@H](O)[C@@H]2O |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (194.86 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.